1st patient doesd in Phase 2 trial testing vaccine for Parkinson's

[PDWarrior1900]

------------

The first patient has been dosed in a Phase 2 clinical trial testing AC Immune’s ACI-7104.056, an investigational vaccine targeting toxic alpha-synuclein forms to prevent nerve cell degeneration in Parkinson’s disease.

AC Immune expects to complete the enrollment of the first group of patients in the VacSYn Phase 2 clinical trial (NCT06015841) and deliver initial safety findings by the year’s end.

The study is now underway at several sites in Germany and Spain, and recruitment is ongoing at certain Spanish sites.

“We continue to progress our pipeline … [with] our [alpha-synuclein] active immunotherapy, ACI-7104.056,” Andrea Pfeifer, AC Immune’s CEO, said in a company press release, noting that three of its treatments will be “in mid- to late-stage clinical testing for neurodegeneration” by the end of this year.

“With further clinical readouts from our precision medicine pipeline ahead, we continue to work diligently towards earlier diagnosis and treatment to prevent progression of neurodegenerative diseases,” Pfeifer added.

parkinsonsnewstoday.com/new...

[ZebraDoodle]

Does anyone know what the implications of the term ’investigational’ are? Does this mean it’s somehow just a proof of concept and unlikely to ever go into production? Sorry if that’s a negative post just trying to temper my expectations…